Alberto-Culver
This article was originally published in The Rose Sheet
Executive Summary
Consumer product division sales grew 10.8% in fiscal Q2 (ended March 31) to $330.2 mil., driven by the continued strength of Tresemme hair care and new products introduced under Alberto VO5 and St. Ives brands in the U.S. and abroad, President & CEO Howard Bernick reports during April 28 conference call. Firm's Beauty Systems Group division had a "challenging year due to a loss of sales and sales force disruption resulting from certain full service product line disruption changes in the United States," company says. Alberto reported Q2 net sales of $884.1 mil., a 7.9% increase, while net earnings grew 20.9% to $49.1 mil. including a non-cash charge related to the company's conversion to one class of common stock in the first quarter of 2004...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.